You are here

Restoration of vestibular hair cells induced by AdMath1

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 1R41DC007772-01
Agency Tracking Number: DC007772
Amount: $138,575.00
Phase: Phase I
Program: STTR
Solicitation Topic Code: N/A
Solicitation Number: N/A
Timeline
Solicitation Year: N/A
Award Year: 2005
Award Start Date (Proposal Award Date): N/A
Award End Date (Contract End Date): N/A
Small Business Information
Genvec, Inc. 65 W Watkins Mill Rd
Gaithersburg, MD 20878
United States
DUNS: N/A
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 DOUGLAS BROUGH
 (240) 632-5540
 dbrough@genvec.com
Business Contact
Phone: (240) 632-5537
Research Institution
 UNIVERSITY OF KANSAS
 
UNIVERSITY OF KANSAS LAWRENCE, KS 66045
LAWRENCE, KS 66045
United States

 Nonprofit College or University
Abstract

Loss of vestibular hair cells can occur due to a variety of disorders and results in dysfunction of the vestibulo-occular reflex and loss of balance. Bilateral vestibular hypofunction due to
aminoglycoside ototoxicity and other means is a devastating and currently untreatable chronic
disorder because loss of vestibular hair cells is permanent. To date there is no prosthetic device
such as a hearing aid or cochlear implant for loss of vestibular function. Complete recovery from
vestibular loss may only be possible through replacement of the missing vestibular sensory cells
and therefore it is important to investigate strategies for the restoration of vestibular sensory cells as potential treatment for these patients. During normal embryonic developmental the genesis of both auditory and vestibular hair cells depends on expression of the atonal homolog, math1.
Recently we have demonstrated that delivery of the mathl gene can induce replacement of hair
cells after aminoglycoside ototoxicity. Although a number of different vectors are capable of
delivering genes to the inner ear, we have focused on the use of adenovectors because they induce transient gene expression, have well defined tropism that can be further modified, have a good safety record in clinical testing and are readily manufactured under GMP. In this phase I STTR we propose to translate our early research findings to more complete proof of feasibility of the product concept. Our objectives are to 1.) test if the mathl induced regeneration of sensory cells is due to transdifferentiation of cells in damaged sensory neuroepithelium, and 2.)
determine if there is a relationship between the restoration of sensory cells and the
delivered dose of vector expressing mathl. Phase II experiments will focus on the selection of
an optimized vector design for formal preclinical testing. Our overall goal is to develop-a viable
inner ear drug for balance disorders designed to treat bilateral vestibular hypofunction.

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government